Lupin Pithampur facilities complete successful MHRA inspection
New Delhi: Pharma major Lupin on Monday said the UK Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory agency of the United Kingdom, has completed the inspection at its three manufacturing plants in the country. The inspection of the three units at Pithampur closed with no critical observation and one major observation, the pharma major said in a filing to BSE.
"We are pleased with the outcome of the inspection by the UK MHRA. It is a meaningful development for our Pithampur facilities. We uphold the highest quality standards across all our manufacturing sites and are committed to maintain global benchmarks," Lupin Managing Director Nilesh Gupta said.
The shares of Lupin were trading at Rs 740.50 a piece on BSE in the morning trade, up 0.05 per cent from the previous close. SID DRR.